CI
REGN icon

Corient IA’s Regeneron Pharmaceuticals REGN Stock Holding History

Corient IA’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Hold
180
– – 0.1% 214
2026
Q1 		$139K Buy
+180
New +$138K 0.13% 239
2025
Q3 		– Sell
-500
Closed -$263K – 267
2025
Q2 		$263K Hold
500
– – 0.15% 243
2025
Q1 		$317K Buy
+500
New +$344K 0.23% 187

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Corient IA's REGN Position: Q2 2026 in Review

Corient IA held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 180 shares worth $112K. The position accounts for 0.1% of the portfolio, ranked #214.

Corient IA first reported a position in REGN in Q1 2025 and has held it in 4 quarters since. The position peaked at $317K in Q1 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Corient IA held 180 shares of Regeneron Pharmaceuticals worth $112K as of Q2 2026.
  • Corient IA left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.1% of Corient IA's portfolio in Q2 2026, its #214 holding.
  • Corient IA first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Corient IA's Regeneron Pharmaceuticals position peaked at $317K in Q1 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.